Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
WGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.88 - $136.00
Previous CloseN/A
Volume338.68K
Average Volume (3M)630.12K
Market Cap
$3.67B
Enterprise Value$2.73B
Total Cash (Recent Filing)$134.56M
Total Debt (Recent Filing)$62.70M
Price to Earnings (P/E)6840.6
Beta1.23
Next Earnings
Nov 17, 2025EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding28,726,248
10 Day Avg. Volume484,111
30 Day Avg. Volume630,115
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue7.53
Enterprise Value/Gross Profit11.21
Enterprise Value/Ebitda119.43
Forecast
1Y Price Target
$121.83Price Target Upside-6.79% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Guideline ChangesNew guidelines from the AAP now recommend exome/genome as a first-line test for kids with development delay & intellectual disability, opening a big opportunity for WGS to access general pediatricians.
Market ExpansionThe '25 outlook now calls for substantial revenue growth in a market that is still largely untapped, making an attractive investment case.
Market OpportunityThe NICU represents a $1B opportunity, with a majority of top NICUs having already ordered from WGS, and several health systems signed up.
Bears Say
Stock VolatilityWhile Q1 exome/genome revenue grew 62% Y/Y, the stock sold off by >50% due to perceived sequential slowdown.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $35.88 and its highest was $136.00 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $3.67B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Nov 17, 2025 which is in 59 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Jul 29, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.116 by $0.384.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Overvalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.41.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 28,726,248 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.5 in its last earnings report, beating expectations of $0.116. Following the earnings report the stock price went up 8.091%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$121.83 (-6.79% Downside)
$121.83 (-6.79% Downside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 599.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
244.42%
12-Months-Change
Fundamentals
Return on Equity
0.60%
Trailing 12-Months
Asset Growth
19.21%
Trailing 12-Months
Company Description
GeneDx Holdings
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
WGS Company Deck
WGS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant revenue growth, record high margins, and successful integration into new markets like NICU. However, challenges remain in expanding into the general pediatrics market and gaining broader payer coverage.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$121.83
▼(-6.79% Downside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
60.46% Insiders
17.25% Mutual Funds
0.40% Other Institutional Investors
13.60% Public Companies and Individual Investors